3 March 2021 - BLA submitted with FDA’s breakthrough therapy designation.
Shanghai Junshi Biosciences and Coherus Biosciences announced today the initiation of the rolling submission of the biologics license application for toripalimab to the U.S. FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma.